Oscar Health (OSCR) AI Stock Analysis

• Market Cap: $5.20B
• Dividend Yield: N/A
• Average Volume (3M): 16.73M
• Price to Earnings (P/E): 77.0
• Beta (1Y): 0.88
• Revenue Growth: 54.26%
• EPS Growth: N/A
• Country: US
• Employees: 2,400
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Healthcare Plans
• EPS (TTM): 0.92
• Shares Outstanding: 219,163,000
• 10 Day Avg. Volume: 28,881,357
• 30 Day Avg. Volume: 16,728,318
• PEG Ratio: 0.09
• Price to Book (P/B): 0.59
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 1.49
• Enterprise Value/Market Cap: -0.14
• Enterprise Value/Revenue: -0.02
• Enterprise Value/Gross Profit: -0.07
• Enterprise Value/Ebitda: -1.61
• 1Y Price Target: $15.30
• Price Target Upside: -25.18% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 6

• Rating: 76 Outperform
• Price Target: $23.50 ▲(14.91%Upside)

Oscar Health's strong financial performance and positive earnings call are offset by high valuation concerns and technical indicators suggesting an overbought condition. While the company is on a solid financial trajectory, potential investors should be cautious of the current valuation and regulatory challenges.

Positive Factors

Financial Performance

OSCR reported 1Q25 EBITDA that beat expectations and reiterated guidance.

Membership Growth

The membership increased by over 100,000, which helped calm investors who were expecting difficulties.

Revenue Growth

OSCR reported solid results, with revenue 7% above consensus driven by stronger than expected membership growth.

Negative Factors

Enrollment Declines

OSCR's main geographic markets, representing a significant portion of its members, are expected to face large enrollment declines, affecting the company's revenue and operating margin.

Financial Health Concerns

MLR missed, raising concerns about the financial health of the company.

Regulatory Challenges

The expiration of enhanced advanced premium tax credits and regulatory crackdowns could lead to adverse risk pool shifts and structurally lower margins.

Oscar Health Business Overview & Revenue Model

Company Description

Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payor clients to engage with members and patients. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

How the Company Makes Money

Oscar Health makes money primarily through the collection of premiums from its members who enroll in its health insurance plans. The company's revenue streams include individual and family plans, small group plans, and Medicare Advantage plans. Oscar Health receives payments from members or sponsors, such as employers, who provide health insurance coverage. Additionally, the company may receive government subsidies for certain plans, particularly those offered under the Affordable Care Act. Oscar also generates revenue by managing healthcare utilization and costs effectively, as it shares in the savings if the cost of medical claims is lower than expected under value-based care arrangements. Partnerships with healthcare providers and a focus on preventive care and telemedicine also contribute to managing expenses and improving profitability.

Oscar Health Financial Statement Overview

Summary

Oscar Health has shown a positive financial trajectory with substantial revenue growth, improving profitability metrics, and strong cash flow generation. The balance sheet is solid with low leverage and improving equity, though there's room for improvement in the equity ratio.

Income Statement

Oscar Health has demonstrated a strong revenue growth trajectory, with a significant increase in total revenue from $4.1 billion in 2022 to $10.08 billion in TTM (Trailing-Twelve-Months) 2025. The gross profit margin remains robust at 100%, indicating efficient cost management. Net profit margin has improved from negative figures to 1.22% in TTM 2025, showing progress towards profitability. EBIT and EBITDA margins have also improved, reflecting better operational efficiency.

Balance Sheet

The company's balance sheet shows a solid equity base, with stockholders' equity rising from negative in 2020 to $1.33 billion in TTM 2025. The debt-to-equity ratio is low at 0.22, indicating conservative leverage. Return on equity has turned positive, reflecting enhanced profitability. However, the equity ratio is at 22.81%, suggesting potential room for improvement in equity financing.

Cash Flow

Oscar Health has shown strong cash flow generation, with free cash flow increasing from negative figures to $1.19 billion in TTM 2025. The free cash flow to net income ratio is healthy, indicating efficient cash management. Operating cash flow to net income ratio is high, demonstrating the company's ability to convert earnings into cash effectively.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.08B	9.18B	5.86B	4.13B	1.92B	589.64M
Gross Profit	10.08B	9.18B	5.86B	4.13B	1.92B	589.64M
EBITDA	197.58M	88.62M	-212.00M	-572.17M	-551.25M	-390.97M
Net Income	123.33M	25.43M	-270.73M	-609.55M	-571.43M	-406.82M
Balance Sheet
Total Assets	5.84B	4.84B	3.60B	4.53B	3.32B	2.27B
Cash, Cash Equivalents and Short-Term Investments	2.99B	2.15B	2.56B	2.96B	1.69B	1.19B
Total Debt	299.75M	299.56M	298.78M	298.00M	0.00	142.49M
Total Liabilities	4.51B	3.82B	2.80B	3.63B	440.02M	3.57B
Stockholders Equity	1.33B	1.01B	803.97M	890.38M	1.39B	-1.30B
Cash Flow
Free Cash Flow	1.19B	950.30M	-297.74M	351.34M	-207.63M	208.71M
Operating Cash Flow	1.22B	978.19M	-272.16M	380.35M	-181.75M	222.73M
Investing Cash Flow	-1.26B	-1.39B	577.19M	-226.52M	-774.51M	-344.71M
Financing Cash Flow	45.95M	68.39M	6.45M	301.11M	1.24B	611.71M

Oscar Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 20.45
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSCR, the sentiment is Neutral. The current price of 20.45 is above the 20-day moving average (MA) of 17.36, above the 50-day MA of 15.67, and above the 200-day MA of 15.71, indicating a neutral trend. The MACD of 1.31 indicates Negative momentum. The RSI at 47.08 is Neutral, neither overbought nor oversold. The STOCH value of 50.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for OSCR.

Oscar Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HUM	77 Outperform	$30.48B	17.86	10.09%	1.45%	10.09%	-12.18%
OSCR	76 Outperform	$5.20B	76.96	10.43%	―	54.26%	―
MOH	72 Outperform	$16.60B	11.54	26.72%	―	16.71%	12.23%
CNC	71 Outperform	$28.19B	8.43	12.59%	―	8.85%	33.30%
ALHC	55 Neutral	$2.81B	―	-75.82%	―	49.12%	43.50%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
CLOV	50 Neutral	$1.40B	―	-7.75%	―	-32.45%	80.24%

Oscar Health Corporate Events

Oscar Health Holds 2025 Annual Stockholders Meeting

On June 4, 2025, Oscar Health, Inc. held its 2025 Annual Meeting of Stockholders, where a quorum was established with 825,961,296 votes represented. During the meeting, nine directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis, indicating shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (OSCR) stock is a Sell with a $13.50 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.